Flanvotumab

Names

[ Name ]:
Flanvotumab

Biological Activity

[Description]:

Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance[1].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Metabolic Enzyme/Protease >> Tyrosinase

[In Vitro]

Flanvotumab is based on TA99, a murine IgG2a anti-TYRP1 mAb, localizes to subcutaneous melanoma xenografts and inhibits syngeneic tumor growth in preclinical models[1]. TA99 exhibits antitumor effect depending on the intact antibody, the presence of Fc receptor, and natural killer (NK) cells[1].

[References]

[1]. Khalil DN, et al. An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. Clin Cancer Res. 2016 Nov 1;22(21):5204-5210.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.